Council on Family Health
Former FDA Commissioner Arthur Hull Hayes, MD, re-elected chairman of the drug industry educational service group; William Bergman, who retired as president of Richardson-Vicks USA, re-elected president; newly elected board members are Schering-Plough Exec VP David Collins and Procter & Gamble Group VP Malcolm Jozoff.
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.